GlassScriptPhysician profile
Tammy E Stallings
NPI 1417290412
$5,668.74
in general payments reported to CMS, 2019-2025
36 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $336 · 2021: $590 · 2022: $1,209 · 2023: $895 · 2024: $965 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,728.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.67 | 2021-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.04 | 2019-2024 | Jardiance |
| Amgen INC. | $508.87 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $461.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $447.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $395.27 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Pfizer INC. | $382.83 | 2019-2025 | |
| Lilly USA, LLC | $348.57 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $285.76 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $256.75 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $172.88 | 2019-2022 | |
| Exact Sciences Corporation | $134.09 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $118.65 | 2022 | |
| Sumitomo Pharma America, INC. | $117.52 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.44 | 2019-2023 | Trulance, Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $74.04 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $68.36 | 2021 | |
| Mylan Specialty L.P. | $67.20 | 2021-2024 | Yupelri |
| Genentech USA, INC. | $54.04 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $42.82 | 2022-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $38.09 | 2023-2024 | |
| Dynavax Technologies Corporation | $34.07 | 2022-2024 | Heplisav-B |
| Currax Pharmaceuticals LLC | $33.16 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $30.93 | 2020-2021 | |
| Dexcom, INC. | $28.12 | 2021-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $27.34 | 2021-2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $26.25 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.67 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $19.68 | 2022 | |
| Lundbeck LLC | $18.37 | 2024 | Rexulti |
| Radius Health, INC. | $16.83 | 2020 | |
| Alfasigma USA, INC. | $16.50 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.53 | 2025 | Voquezna |
| Eisai INC. | $14.05 | 2021 | |
| Allergan, INC. | $13.36 | 2020 | |
| Amarin Pharma, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Stallings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.